Qualifyze is a technology company.
Qualifyze provides AI-powered solutions for quality oversight and site risk management, focusing on compliance and supplier qualification in the life sciences sector.
Qualifyze has raised $72.0M across 4 funding rounds.
Qualifyze has raised $72.0M in total across 4 funding rounds.
Qualifyze is a technology company founded in 2019 that provides an AI-powered platform for quality oversight, audit management, and site risk management in the life sciences industry, particularly pharmaceuticals and healthcare. It builds a cloud-based Audit Platform and Quality Insights Platform, serving over 1,000–1,200 clients including pharma manufacturers and suppliers by centralizing access to the world's largest GxP audit database (5,000+ reports, with 450+ added monthly), enabling real-time audit tracking, predictive risk insights, digital CAPA management, and data-driven procurement decisions.[1][2][3][4] The platform solves critical supply chain compliance challenges—such as spotting issues early, accelerating supplier qualification by 65%, reducing audit costs by 40%, and mitigating disruptions from volatility like tariffs—through proactive AI analytics and a global network of expert auditors.[1][3]
Qualifyze was established in Germany in 2019 as a traditional auditing firm focused on pharmaceutical excellence and supply chain quality standards.[2][3] CEO David Schneider leads the company, which evolved rapidly by layering advanced technology onto its audit services after recognizing the limitations of point-in-time assessments.[3] This pivot created a digital platform leveraging the largest global dataset of supplier audits, enhanced by AI and data analytics for real-time compliance monitoring and forecasting.[1][2][3] Early traction came from building a secure, cloud-based system that connects manufacturers, suppliers, and quality professionals, now trusted by over 1,000 clients and backed by investors like Insight Partners.[2][4] Pivotal moments include shifting to AI-driven insights for stakeholder alignment across quality, procurement, and supply chain teams, accelerating decisions like product launches via pre-qualified supplier data.[3]
Qualifyze stands out in pharma compliance through these key strengths:
Qualifyze rides the AI-driven supply chain resilience trend in life sciences, where increasing market volatility (e.g., tariffs) and regulatory demands amplify risks in global pharma manufacturing.[3] Its timing aligns with post-pandemic scrutiny on supplier qualification, enabling faster, informed decisions amid fragmented data—combining traditional GxP compliance with predictive analytics to prevent disruptions and support sustainable supply chains.[1][2][3] Market forces like rising compliance costs and the need for real-time insights favor its model, influencing the ecosystem by standardizing data sharing, accelerating product launches, and empowering procurement with pre-qualification views, thus reducing industry-wide audit bottlenecks.[3][4]
Qualifyze is poised for expansion by deepening AI enhancements on its audit dataset, potentially integrating more sustainability metrics and API-driven ecosystems for broader enterprise adoption. Trends like escalating pharma volatility and AI adoption in compliance will propel growth, evolving its influence from audit efficiency to full supply chain orchestration. As a leader trusted by 1,200+ clients, it will continue transforming reactive quality management into proactive resilience, safeguarding global pharma excellence.[1][3][4]
Qualifyze has raised $72.0M in total across 4 funding rounds.
Qualifyze's investors include Cherry Ventures, Costanoa Ventures, Creandum, DN Capital, FirstMark Capital, Christian Miele, HV Capital, Insight Partners, Menlo Ventures, SoftBank Investment Advisers, Ten Eleven Ventures, Threshold Ventures.
Qualifyze has raised $72.0M across 4 funding rounds. Most recently, it raised $54.0M Series B in September 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2024 | $54.0M Series B | Cherry Ventures, Costanoa Ventures, Creandum, DN Capital, FirstMark Capital, Christian Miele, HV Capital, Insight Partners, Menlo Ventures, SoftBank Investment Advisers, Ten Eleven Ventures, Threshold Ventures, Julius Köhler, Mato Peric | |
| Aug 1, 2023 | $12.0M Venture Round | Creandum, HV Capital, Julius Köhler | |
| Aug 1, 2020 | $4.0M Seed | ||
| Jun 1, 2019 | $2.0M Seed | Cherry Ventures, Costanoa Ventures, DN Capital, FirstMark Capital, Christian Miele, SoftBank Investment Advisers, Threshold Ventures, Mato Peric |